Share this page:
Other services (opens in new window)
Sets a cookie

Epigenetic answers from archived Guthrie cards

23 August 2012

Blood is spotted onto a Guthrie card. Credit: Ake Lernmark

Blood is spotted onto a Guthrie card.
Credit: Åke Lernmark

Over the last 50 years, the spotting of newborn's blood onto filter paper for disease screening, called Guthrie cards, has become routine. In a study published online in Genome Research, researchers have shown that epigenetic information stored on archived Guthrie cards provides a retrospective view of the epigenome at birth, a powerful new application for the card that could help understand disease and predict future health.

DNA methylation, an epigenetic chemical modification of DNA, is known to affect gene activity and play a role in normal development, aging, and also in diseases such as heart disease, diabetes, and cancer. "But are these epigenetic marks involved in causing the disease, or a result of the disease itself?" asked Dr. Vardhman Rakyan of Queen Mary, University of London and co-senior author of the study. Rakyan explained that this is impossible to know when samples are obtained after onset of the disease.

Guthrie cards, commonly used to collect blood spots from the pricked heel of newborns to screen for diseases such as phenylketonuria, cystic fibrosis, and sickle cells disorders, might offer a snapshot of the epigenome before disease develops. Many Guthrie cards are stored indefinitely by health authorities around the world, posing a potential wealth of information about the epigenome at birth.

A newborn's blood is spotted onto a Guthrie card. Credit: The New York State Department of Health Newborn Screening Program

A newborn's blood is spotted onto a Guthrie card. Commonly used to collect blood spots from the pricked heel of newborns to screen for diseases such as phenylketonuria, cystic fibrosis, and sickle cells disorders, Guthrie cards might offer a snapshot of the epigenome before disease develops.
Credit: The New York State Department of Health Newborn Screening Program

Rakyan and an international group of colleagues purified genomic DNA and analysed DNA methylomes from Guthrie cards and verified that this archived DNA yields high-quality methylation data when compared to fresh samples. The researchers then compared the DNA methylation profiles of newborns to the same healthy individuals at the age of three, looking for epigenetic variations detected in the Guthrie card sample that are stable into the early years of life.

"We found similar epigenetic differences between different people both at birth and when they were three years old," said Rakyan, who added that these differences, already present at birth, are unlikely due solely to inherent genetic differences between the individuals, but also due to environment or random events in utero. Furthermore, Guthrie card samples could be analysed for both genetic and epigenetic differences together to view a more complete picture of the genome at birth.

Guthrie card methylomics is a potentially powerful new application for archived blood spots, which could provide a wealth of information about epigenetics and disease, and could give clues about health later in life. Dr. David Leslie, co-senior author of the study, added that because national health authorities routinely make Guthrie cards available, and with the proper consent obtained from parents and children, "we are talking about an invaluable, and non-renewable, resource for millions of individuals."

Scientists from Queen Mary, University of London (London, UK), the University of Cambridge (Cambridge, UK), the University of Oxford (Oxford, UK), Skåne University Hospital (Malmö, Sweden), and University Medical Centre Ulm (Ulm, Germany) contributed to this study.

This work was supported by The Knut and Alice Wallenberg Foundation, the Swedish Research Council, the Skåne County Council for Research and Development, the Biotechnology and Biological Sciences Research Council (UK), Juvenile Diabetes Research Foundation International, the Multiple Sclerosis Society of the United Kingdom, and the Medical Research Council (UK).

ENDS

About BBSRC

BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by Government, and with an annual budget of around £445M (2011-2012), we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

For more information about BBSRC, our science and our impact see: www.bbsrc.ac.uk.
For more information about BBSRC strategically funded institutes see: www.bbsrc.ac.uk/institutes.